Valneva SE (INRLF)
USD 1.98
(0.0%)
USD 1.98
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 132.76 Million EUR | 15.06% |
| 2022 | 115.39 Million EUR | 10.51% |
| 2021 | 104.41 Million EUR | 9.03% |
| 2020 | 95.76 Million EUR | 18.36% |
| 2019 | 80.9 Million EUR | 101.92% |
| 2018 | 40.07 Million EUR | -25.93% |
| 2017 | 54.09 Million EUR | -12.1% |
| 2016 | 61.54 Million EUR | -19.62% |
| 2015 | 76.56 Million EUR | 15.95% |
| 2014 | 66.03 Million EUR | 1.75% |
| 2013 | 64.9 Million EUR | 1179.36% |
| 2012 | 5.07 Million EUR | -3.7% |
| 2011 | 5.26 Million EUR | -4.93% |
| 2010 | 5.54 Million EUR | 3.36% |
| 2009 | 5.36 Million EUR | 38.74% |
| 2008 | 3.86 Million EUR | 23.69% |
| 2007 | 3.12 Million EUR | 8.17% |
| 2006 | 2.88 Million EUR | 6.61% |
| 2005 | 2.7 Million EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 159.03 Million EUR | 19.78% |
| 2024 Q2 | 160.54 Million EUR | 0.95% |
| 2023 Q2 | 102.09 Million EUR | -9.47% |
| 2023 Q4 | 132.76 Million EUR | -1.58% |
| 2023 FY | 132.76 Million EUR | 15.06% |
| 2023 Q3 | 134.89 Million EUR | 32.13% |
| 2023 Q1 | 112.78 Million EUR | -2.26% |
| 2022 Q2 | 118.98 Million EUR | 147.87% |
| 2022 Q1 | 48 Million EUR | -54.02% |
| 2022 Q4 | 115.39 Million EUR | -20.97% |
| 2022 FY | 115.39 Million EUR | 10.51% |
| 2022 Q3 | 146 Million EUR | 22.71% |
| 2021 Q2 | 101.31 Million EUR | 3.96% |
| 2021 FY | 104.41 Million EUR | 9.03% |
| 2021 Q1 | 97.46 Million EUR | 1.77% |
| 2021 Q4 | 104.41 Million EUR | 0.0% |
| 2020 Q3 | 101.21 Million EUR | -1.47% |
| 2020 Q4 | 95.76 Million EUR | -5.39% |
| 2020 Q2 | 102.72 Million EUR | 13.08% |
| 2020 Q1 | 90.84 Million EUR | 12.28% |
| 2020 FY | 95.76 Million EUR | 18.36% |
| 2019 FY | 80.9 Million EUR | 101.92% |
| 2019 Q1 | 72.28 Million EUR | 80.39% |
| 2019 Q4 | 80.9 Million EUR | 1.05% |
| 2019 Q3 | 80.06 Million EUR | 14.35% |
| 2019 Q2 | 70.02 Million EUR | -3.13% |
| 2018 FY | 40.07 Million EUR | -25.93% |
| 2018 Q1 | 41.15 Million EUR | -23.92% |
| 2018 Q4 | 40.07 Million EUR | -0.61% |
| 2018 Q3 | 40.31 Million EUR | 3.29% |
| 2018 Q2 | 39.03 Million EUR | -5.16% |
| 2017 Q4 | 54.09 Million EUR | 4.08% |
| 2017 FY | 54.09 Million EUR | -12.1% |
| 2017 Q2 | 54.14 Million EUR | -5.88% |
| 2017 Q1 | 57.52 Million EUR | -6.53% |
| 2017 Q3 | 51.97 Million EUR | -4.01% |
| 2016 Q4 | 61.54 Million EUR | -2.1% |
| 2016 FY | 61.54 Million EUR | -19.62% |
| 2016 Q3 | 62.86 Million EUR | -3.01% |
| 2016 Q2 | 64.81 Million EUR | -7.39% |
| 2016 Q1 | 69.98 Million EUR | -8.59% |
| 2015 Q4 | 76.56 Million EUR | -5.26% |
| 2015 Q1 | 86.05 Million EUR | 30.31% |
| 2015 FY | 76.56 Million EUR | 15.95% |
| 2015 Q2 | 83.38 Million EUR | -3.1% |
| 2015 Q3 | 80.81 Million EUR | -3.08% |
| 2014 Q4 | 66.03 Million EUR | 2.13% |
| 2014 FY | 66.03 Million EUR | 1.75% |
| 2014 Q3 | 64.65 Million EUR | 1.61% |
| 2014 Q2 | 63.63 Million EUR | -0.68% |
| 2014 Q1 | 64.06 Million EUR | -1.29% |
| 2013 Q4 | 64.9 Million EUR | 45.08% |
| 2013 FY | 64.9 Million EUR | 1179.36% |
| 2013 Q3 | 44.73 Million EUR | -4.32% |
| 2013 Q2 | 46.75 Million EUR | 0.0% |
| 2013 Q1 | - EUR | -100.0% |
| 2012 FY | 5.07 Million EUR | -3.7% |
| 2012 Q2 | 4.6 Million EUR | 0.0% |
| 2012 Q4 | 5.07 Million EUR | 0.0% |
| 2011 FY | 5.26 Million EUR | -4.93% |
| 2011 Q2 | 6.16 Million EUR | 0.0% |
| 2011 Q4 | 5.26 Million EUR | 0.0% |
| 2010 FY | 5.54 Million EUR | 3.36% |
| 2010 Q2 | 5.75 Million EUR | 0.0% |
| 2010 Q4 | 5.54 Million EUR | 0.0% |
| 2009 Q4 | 5.36 Million EUR | 0.0% |
| 2009 FY | 5.36 Million EUR | 38.74% |
| 2008 FY | 3.86 Million EUR | 23.69% |
| 2007 FY | 3.12 Million EUR | 8.17% |
| 2006 FY | 2.88 Million EUR | 6.61% |
| 2005 FY | 2.7 Million EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | - USD | -Infinity% |
| SQZ Biotechnologies Company | 20.9 Million USD | -534.98% |
| Evofem Biosciences, Inc. | 8000.00 USD | -1659500.0% |
| Santhera Pharmaceuticals Holding AG | 1.75 Million USD | -7463.064% |
| Mesoblast Limited | 100.29 Million USD | -32.378% |
| Propanc Biopharma, Inc. | 58.64 Thousand USD | -226304.284% |
| Genus plc | 228.2 Million USD | 41.819% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | - USD | -Infinity% |
| Marizyme, Inc. | 667.12 Thousand USD | -19801.398% |
| ContraFect Corporation | 2.21 Million USD | -5907.602% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.4 Million USD | -9363.596% |
| Intellipharmaceutics International Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 5.42 Million USD | -2346.669% |
| MultiCell Technologies, Inc. | 36.43 USD | -364446784.436% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 55.61 Million USD | -138.74% |
| EV Biologics, Inc. | - USD | -Infinity% |
| Q BioMed Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 2.22 Million USD | -5864.42% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -10708.549% |
| Biomind Labs Inc. | - USD | -Infinity% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 166.1 Million USD | 20.07% |
| Oncotelic Therapeutics, Inc. | 1.89 Million USD | -6893.428% |
| Skye Bioscience, Inc. | 171.23 Thousand USD | -77437.815% |
| Therapeutic Solutions International, Inc. | 5512.00 USD | -2408608.273% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | - USD | -Infinity% |
| IMV Inc. | 27.39 Million USD | -384.58% |
| Acro Biomedical Co., Ltd. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | 322 Thousand USD | -41132.298% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 11.23 Billion USD | 98.819% |
| Halberd Corporation | 150 Thousand USD | -88412.0% |
| Enzolytics Inc. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 300 Thousand USD | -44156.0% |
| Nuo Therapeutics, Inc. | 164.2 Thousand USD | -80755.029% |
| argenx SE | 15.35 Million USD | -764.713% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 20.31 Million USD | -553.643% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 4456.00 USD | -2979433.214% |
| Genscript Biotech Corporation | 287.12 Million USD | 53.76% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 126.3 Thousand USD | -105019.476% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -57803.712% |
| American Oriental Bioengineering, Inc. | 554.59 Thousand USD | -23839.847% |
| Provectus Biopharmaceuticals, Inc. | 25.29 Thousand USD | -524695.446% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 8.26 Million USD | -1506.583% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 265.63 Thousand USD | -49881.365% |
| ONE Bio Corp. | 592.19 Thousand USD | -22319.529% |
| Reve Technologies, Inc. | 1064.00 USD | -12478095.489% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -88640.359% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -88640.359% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 229.69 Thousand USD | -57702.874% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| CytoDyn Inc. | 141 Thousand USD | -94061.702% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 80 Thousand USD | -165860.0% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -1597.809% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 369.04 Thousand USD | -35875.711% |
| International Stem Cell Corporation | 445 Thousand USD | -29735.506% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.15 Million USD | -1529.055% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | 457 Thousand USD | -28952.079% |
| Neutra Corp. | - USD | -Infinity% |
| Windtree Therapeutics, Inc. | 1.16 Million USD | -11335.659% |
| PureTech Health plc | 18.25 Million USD | -627.496% |
| Coeptis Therapeutics, Inc. | 150 Thousand USD | -88412.0% |
| IXICO plc | 275 Thousand USD | -48179.273% |
| IntelGenx Technologies Corp. | 11.83 Million USD | -1021.446% |
| Gelesis Holdings, Inc. | 26.3 Million USD | -404.649% |
| CSL Limited | 11.23 Billion USD | 98.819% |
| Cellectis S.A. | 36.21 Million USD | -266.65% |